Phase 2 Randomized, Non-Comparative Study of Ticilimumab or Best Supportive Care Immediately Following First-Line, Platinum-Based Therapy in Patients with STage IIIB (with effusion) IV Non-Small Cell Lung Cancer that has Responded or Remained Stable